TuisPHS • FRA
add
Photocure ASA
Vorige sluiting
€4,20
Dagwisseling
€4,16 - €4,16
Jaarwisseling
€4,01 - €6,13
P/V-verhouding
-
Dividend-opbrengs
-
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (NOK) | Jun. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 145,45 m | 0,78% |
Bedryfskoste | 117,16 m | -2,85% |
Netto inkomste | 12,33 m | 186,06% |
Netto winsgrens | 8,48 | 183,61% |
Wins per aandeel | 0,45 | 181,25% |
EBITDA | 27,85 m | 19,06% |
Effektiewe belastingkoers | 23,70% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (NOK) | Jun. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 266,99 m | 3,11% |
Totale bates | 713,58 m | 0,99% |
Totale aanspreeklikheid | 213,92 m | -10,51% |
Totale ekwiteit | 499,66 m | — |
Uitstaande aandele | 27,11 m | — |
Prys om te bespreek | 0,23 | — |
Opbrengs op bates | 7,23% | — |
Opbrengs op kapitaal | 10,18% | — |
Kontantvloei
Netto kontantverandering
| (NOK) | Jun. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 12,33 m | 186,06% |
Kontant van bedrywe | 19,52 m | -32,96% |
Kontant van beleggings | 472,00 k | 265,89% |
Kontant van finansiering | -11,27 m | 31,02% |
Netto kontantverandering | 8,72 m | -32,43% |
Beskikbare kontantvloei | 5,25 m | -65,93% |
Meer oor
Photocure ASA is a Norwegian specialty pharma company that develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology. Photocure's strategy in cancer is to continue the commercialization of Hexvix for bladder cancer diagnostics, and continue the development of the cancer portfolio and out-license prior to phase III studies. This strategy is based on a strong platform of intellectual property in photodynamic therapy. Wikipedia
Gestig
1993
Webwerf
Werknemers
102
